Sana Biotechnology, Inc.
NASDAQ:SANA · NASDAQ Global Select
+$0.04 today
Vol 4.71M · Avg 3.76M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-151.8%
avg -25.0%
ROIC
-54.1%
avg -40.3%
ROA
-58.6%
avg -41.9%
Analysis
ROIC is currently the strongest return metric at -54.1% versus its period average of -40.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steven D. Harr | President, Chief Executive Officer & Director | $1.15M | — | 56 | $196,196.00 | 0.07% |
Brian D. Piper | Executive Vice President & Chief Financial Officer | $653,044.00 | — | 54 | $196,196.00 | 0.07% |
Aaron Grossman | Executive VP, Chief Legal Officer & Corporate Secretary | — | — | 54 | — | — |
John Gerecitano | Head of Oncology Research & Development | — | — | — | — | — |
Snehal Patel | Senior Vice President & Chief Technical Officer | — | — | — | $99,510.00 | 0.04% |
Dhavalkumar D. Patel | Executive Vice President & Chief Scientific Officer | — | — | 65 | $99,510.00 | 0.04% |
Gary Meininger | Chief Medical Officer | — | — | — | — | — |
Yuko Soneoka | Head of Intellectual Property | — | — | — | — | — |
Debra Wisdom | VP & Head of People | — | — | — | — | — |
Susan Wyrick | Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | — | — | 53 | $196,196.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.38B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.81B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.87B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.70B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.48B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Xencor, Inc.
NASDAQ:XNCR
$937.75M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$855.60M
Oculis Holding AG
NASDAQ:OCS
$628.29M
Who manages SANA?
Sana Biotechnology, Inc. (SANA) lists 10 active executives. The top listed executive is Aaron Grossman, Executive VP, Chief Legal Officer & Corporate Secretary.
Are SANA insiders buying or selling?
Recent insider activity shows net buying of $61.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.